We, and others, have shown that BRAF inhibitors (BRAF-I) enhance the antiproliferative and immunomodulatory effects of IFN-α on BRAFV600E melanoma cells because the inhibition of ERK activation by BRAF-I upregulates IFNAR1 expression on melanoma cells [15]. This evidence concerns the gene IFNA1 and melanoma.